CQUniversity
Browse

Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer

journal contribution
posted on 2018-05-15, 00:00 authored by R Shakya, GA Tarulli, L Sheng, NA Lokman, C Ricciardelli, KI Pishas, CI Selinger, MRJ Kohonen-Corish, WA Cooper, AG Turner
Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the 'secretome') that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial-mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Funding

Category 1 - Australian Competitive Grants (this includes ARC, NHMRC)

History

Volume

36

Issue

31

Start Page

4469

End Page

4480

Number of Pages

12

eISSN

1476-5594

ISSN

0950-9232

Publisher

Nature Publishing Group, UK

Peer Reviewed

  • Yes

Open Access

  • No

Acceptance Date

2017-02-05

External Author Affiliations

UNSW Australia; Garvan Institute of Medical Research, Sydney; University of Sydney; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital;University of Western Sydney; The University of Adelaide

Era Eligible

  • Yes

Journal

Oncogene

Usage metrics

    CQUniversity

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC